{"id":"peginterferon-alfa-2a","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Fatigue","drugRate":"68%","severity":"common"},{"effect":"Pyrexia","drugRate":"55%","severity":"common"},{"effect":"Myalgia","drugRate":"49%","severity":"common"},{"effect":"Headache","drugRate":"48%","severity":"common"},{"effect":"Injection site reaction","drugRate":"23%","severity":"common"},{"effect":"Hypothyroidism","drugRate":"23%","severity":"common"},{"effect":"Nausea/Vomiting","drugRate":"23%","severity":"common"},{"effect":"Diarrhea","drugRate":"16%","severity":"common"},{"effect":"Abdominal pain","drugRate":"15%","severity":"common"},{"effect":"Dry mouth","drugRate":"6%","severity":"mild"},{"effect":"Dyspepsia","drugRate":"6%","severity":"mild"},{"effect":"Lymphopenia","drugRate":"14%","severity":"common"},{"effect":"Anemia","drugRate":"11%","severity":"common"},{"effect":"Neutropenia","drugRate":"27%","severity":"common"},{"effect":"Thrombocytopenia","drugRate":"5%","severity":"mild"},{"effect":"Anorexia","drugRate":"7%","severity":"mild"},{"effect":"Weight decrease","drugRate":"4%","severity":"mild"},{"effect":"Arthralgia","drugRate":"22%","severity":"common"},{"effect":"Back pain","drugRate":"9%","severity":"mild"},{"effect":"Dizziness","drugRate":"11%","severity":"common"},{"effect":"Memory impairment","drugRate":"6%","severity":"mild"},{"effect":"Bacterial infection","drugRate":"3%","severity":"serious"},{"effect":"Suicide","drugRate":"reported","severity":"unknown"},{"effect":"Suicidal ideation","drugRate":"reported","severity":"unknown"},{"effect":"Aggression","drugRate":"reported","severity":"unknown"},{"effect":"Anxiety","drugRate":"reported","severity":"unknown"},{"effect":"Drug abuse","drugRate":"reported","severity":"unknown"},{"effect":"Drug overdose","drugRate":"reported","severity":"unknown"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:46:14.133060","allNames":"pegasys","offLabel":[],"timeline":[],"_dailymed":{"setId":"d9290e5b-6d40-2318-e053-2995a90a9916","title":"PEGASYS (PEGINTERFERON ALFA-2A) INJECTION, SOLUTION [PHARMAAND GMBH]"},"ecosystem":[],"mechanism":{"target":"Interferon alpha/beta receptor"},"_scrapedAt":"2026-03-28T00:38:39.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Chronic hepatitis C","diseaseId":"chronic-hepatitis-c","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic type B viral hepatitis","diseaseId":"chronic-type-b-viral-hepatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","pubmed(587)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06092333","phase":"PHASE2","title":"VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2025-01-31","conditions":"Chronic Hepatitis B","enrollment":50},{"nctId":"NCT07475338","phase":"NA","title":"Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort","status":"NOT_YET_RECRUITING","sponsor":"SKEZI","startDate":"2026-03","conditions":"General Population (no Specific Condition or Disease)","enrollment":500},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT07288112","phase":"PHASE1, PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2026-02-23","conditions":"Refractory Melanoma","enrollment":35},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT01753557","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C (CHC)","enrollment":54},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT02743182","phase":"NA","title":"HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients","status":"COMPLETED","sponsor":"José Antonio Carrion","startDate":"2015-01","conditions":"Chronic Hepatitis B (HBeAg-negative)","enrollment":119},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT04225715","phase":"PHASE2","title":"A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-05","conditions":"Hepatitis B, Chronic","enrollment":281},{"nctId":"NCT01718301","phase":"PHASE3","title":"HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","status":"TERMINATED","sponsor":"Anna Cruceta","startDate":"2013-03-10","conditions":"Hepatitis C, HIV Infections, COINFECTION","enrollment":108},{"nctId":"NCT02992704","phase":"PHASE2, PHASE3","title":"Peg-interferon for Inactive Chronic Hepatitis B Carriers","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2016-08","conditions":"Chronic Hepatitis, B Virus, Carrier of Viral Hepatitis Type B","enrollment":90},{"nctId":"NCT06922643","phase":"PHASE4","title":"Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2011-03-01","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT04439539","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-14","conditions":"Hepatitis B, Chronic","enrollment":54},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT05535764","phase":"PHASE1","title":"Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-08-02","conditions":"Myelofibrosis","enrollment":18},{"nctId":"NCT00442572","phase":"PHASE2","title":"SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07-03","conditions":"Hepatitis B, Chronic","enrollment":21},{"nctId":"NCT01194037","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2011-06-23","conditions":"Chronic Hepatitis C Infection, Genotype 1","enrollment":30},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT05683548","phase":"","title":"Replicor Compassionate Access Program","status":"NO_LONGER_AVAILABLE","sponsor":"Replicor Inc.","startDate":"","conditions":"Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver","enrollment":""},{"nctId":"NCT06144697","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2024-01-29","conditions":"Healthy Participants","enrollment":267},{"nctId":"NCT04426968","phase":"PHASE2","title":"A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2021-06-18","conditions":"Hepatitis B, Chronic","enrollment":96},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT00452023","phase":"PHASE2","title":"Pegasys® in Patients With Myeloproliferative Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-04-07","conditions":"Myeloproliferative Disorders","enrollment":83},{"nctId":"NCT03852433","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-31","conditions":"Chronic Hepatitis Delta","enrollment":175},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT02471430","phase":"PHASE1, PHASE2","title":"Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-05","conditions":"HIV Infection","enrollment":17},{"nctId":"NCT01120795","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2004-02","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT04798612","phase":"PHASE2","title":"Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2023-08-14","conditions":"Colon Cancer","enrollment":68},{"nctId":"NCT00571714","phase":"NA","title":"Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-04-01","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT05729139","phase":"PHASE1","title":"Cemiplimab/Peg-Interferon-α in Advanced CSCC","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2023-07","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02340962","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2015-05","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT05941845","phase":"PHASE2","title":"Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-07-24","conditions":"Membranous Nephropathy","enrollment":5},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT01369212","phase":"PHASE3","title":"Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-11","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT01439776","phase":"PHASE4","title":"Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients","status":"COMPLETED","sponsor":"Hanyang University","startDate":"2011-09","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT02430194","phase":"PHASE2","title":"Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-12","conditions":"Chronic Hepatitis D Infection","enrollment":55},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21},{"nctId":"NCT01519960","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07-11","conditions":"Hepatitis B, Chronic","enrollment":165},{"nctId":"NCT02594293","phase":"PHASE4","title":"Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-10","conditions":"Chronic Hepatitis B","enrollment":180},{"nctId":"NCT02218164","phase":"PHASE2","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-08-12","conditions":"Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell","enrollment":8},{"nctId":"NCT04365933","phase":"PHASE2","title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2020-05-25","conditions":"Hepatitis B, Chronic","enrollment":20},{"nctId":"NCT02742324","phase":"PHASE1, PHASE2","title":"Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2016-03","conditions":"Myelofibrosis","enrollment":37},{"nctId":"NCT01369199","phase":"PHASE3","title":"Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-05","conditions":"Hepatitis B","enrollment":28},{"nctId":"NCT01368497","phase":"PHASE3","title":"Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-09","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":"Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis","enrollment":202},{"nctId":"NCT03575208","phase":"PHASE2","title":"Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-02-13","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT01380938","phase":"PHASE3","title":"Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2018-12-01","conditions":"Chronic Hepatitis","enrollment":1150},{"nctId":"NCT05129644","phase":"PHASE1","title":"Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2009-11-07","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT00051077","phase":"PHASE2","title":"Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Hepatitis C","enrollment":""},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT00008463","phase":"PHASE2","title":"A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections, Hepatitis C","enrollment":132},{"nctId":"NCT01587586","phase":"PHASE2","title":"Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2011-10-18","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT02328755","phase":"PHASE1, PHASE2","title":"Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2015-01","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT03013556","phase":"PHASE4","title":"Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-11","conditions":"Chronic Hepatitis","enrollment":180},{"nctId":"NCT01850745","phase":"","title":"Multidisciplinary Support Program in Chronic Hepatitis C","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2003-01","conditions":"Hepatitis C, Chronic","enrollment":447},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT01941680","phase":"","title":"High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant","status":"COMPLETED","sponsor":"University Hospital Center of Martinique","startDate":"2013-10-31","conditions":"T-cell Lymphoma, Leukaemia","enrollment":20},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT02888106","phase":"PHASE2","title":"Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent","status":"COMPLETED","sponsor":"Hepatera Ltd.","startDate":"2016-04","conditions":"Chronic Viral Hepatitis B With Delta-agent","enrollment":90},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT03181113","phase":"","title":"Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2016-05-18","conditions":"Hepatitis B","enrollment":473},{"nctId":"NCT03294798","phase":"PHASE1, PHASE2","title":"Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-06-13","conditions":"Hepatitis B Virus","enrollment":11},{"nctId":"NCT00973219","phase":"NA","title":"Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-09","conditions":"Chronic Hepatitis B","enrollment":151},{"nctId":"NCT00758043","phase":"PHASE3","title":"A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-10","conditions":"Hepatitis C","enrollment":540},{"nctId":"NCT03020082","phase":"PHASE3","title":"Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":141},{"nctId":"NCT00943761","phase":"PHASE2","title":"A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-23","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01080222","phase":"PHASE2","title":"A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-08","conditions":"Chronic Hepatitis C Virus Infection","enrollment":152},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT02381379","phase":"PHASE3","title":"Malaysia Stop Tyrosine Kinase Inhibitor Trial","status":"UNKNOWN","sponsor":"Ministry of Health, Malaysia","startDate":"2015-03","conditions":"Leukemia, Chronic Myeloid","enrollment":118},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT01741545","phase":"PHASE3","title":"Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-31","conditions":"Hepatitis C Virus","enrollment":71},{"nctId":"NCT00845676","phase":"PHASE4","title":"Treatment of Acute Hepatitis C Virus in HIV Co-Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-03","conditions":"Hepatitis C, Human Immunodeficiency Virus, HIV Infections","enrollment":21},{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT00006164","phase":"PHASE3","title":"Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-06","conditions":"Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver","enrollment":1050},{"nctId":"NCT00219739","phase":"PHASE3","title":"STI571 ProspectIve RandomIzed Trial: SPIRIT","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2003-09","conditions":"Chronic Myeloid Leukemia","enrollment":789},{"nctId":"NCT01524679","phase":"PHASE2","title":"Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":170},{"nctId":"NCT03957629","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-11-06","conditions":"Hepatitis B, Liver Fibrosis","enrollment":186},{"nctId":"NCT00470210","phase":"PHASE4","title":"Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-05","conditions":"Hepatitis C, HIV Infections","enrollment":10},{"nctId":"NCT00356486","phase":"PHASE4","title":"Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-10","conditions":"HIV Infections","enrollment":74},{"nctId":"NCT01373684","phase":"PHASE4","title":"PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-05-25","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT02407080","phase":"PHASE1","title":"Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia","status":"COMPLETED","sponsor":"John Mascarenhas","startDate":"2015-04","conditions":"Polycythemia Vera, Essential Thrombocythemia","enrollment":13},{"nctId":"NCT02565719","phase":"PHASE2","title":"REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2016-03","conditions":"Chronic Hepatitis B","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":587,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Pegasys","genericName":"PEGINTERFERON ALFA-2A","companyName":"Hoffman-La Roche","companyId":"","modality":"Recombinant protein","firstApprovalDate":"2002","aiSummary":"Pegasys (PEGINTERFERON ALFA-2A) is a medication developed by Hoffman-La Roche, targeting the interferon alpha/beta receptor. It belongs to the interferon alpha class and is used to treat chronic hepatitis C and chronic type B viral hepatitis. Pegasys is a small molecule modality, FDA-approved in 2002, and is currently owned by Hoffman-La Roche. The medication works by modulating the immune system to fight viral infections. Its commercial status and key safety considerations are not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":"EMEA/H/C/000395"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pegasys","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":8,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}